Similar Articles |
|
Chemistry World June 18, 2008 Ananyo Bhattacharya |
Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service |
Chemistry World March 7, 2008 Peter Mitchell |
Uk Drug Pricing System Scrapped The UK government is scrapping its existing national scheme for controlling drug prices. The system, called the Pharmaceutical price regulation scheme (PPRS), will be replaced by a newly negotiated agreement on 1 September 2008. |
Pharmaceutical Executive April 1, 2007 Sarah Houlton |
Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change? |
Chemistry World April 2007 Richard Barker |
Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago. |
Chemistry World September 17, 2007 |
Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing. |
Pharmaceutical Executive December 1, 2006 Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
Chemistry World June 11, 2008 James Mitchell Crow |
GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations. |
Pharmaceutical Executive August 1, 2008 Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Pharmaceutical Executive December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Chemistry World April 16, 2010 Sean Milmo |
Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK. |
Chemistry World November 21, 2008 Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
Chemistry World October 26, 2011 Maria Burke |
Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard. |
Pharmaceutical Executive May 1, 2011 Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
Chemistry World December 4, 2012 Andrew Turley |
Drug R&D costs rising Inventing a new drug costs an enormous amount of money. It's part of the reason why the pharma industry is struggling to fill its pipelines. But we'd like to think that -- however slowly -- that cost is coming down. Unfortunately it isn't. |
Chemistry World November 6, 2013 Laura Howes |
Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D. |
Chemistry World September 5, 2014 Emma Stoye |
Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results. |
Pharmaceutical Executive May 1, 2012 |
Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity? |
Chemistry World February 2, 2012 Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Pharmaceutical Executive June 1, 2013 Julian Upton |
Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property. |
Chemistry World March 19, 2013 Simon Hadlington |
Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016. |
Chemistry World April 23, 2013 Emma Stoye |
Invest in research or be left behind, UK academies warn The UK's four national academies have called on the government to increase investment in research over the next decade or risk being overtaken by international competitors. |
Chemistry World January 30, 2014 Phillip Broadwith |
AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India. |
Chemistry World March 22, 2012 Andrew Turley |
GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria. |
Chemistry World May 4, 2006 Katharine Sanderson |
Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise. |
The Motley Fool June 24, 2010 Luke Timmerman |
Amylin Cuts 60 Jobs The pharmaceutical company says research is still a priority. |
Chemistry World February 2, 2007 Victoria Gill |
AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits. |
Chemistry World February 18, 2010 Matt Wilkinson |
Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut. |
Chemistry World October 1, 2008 Victoria Gill |
GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy. |
Chemistry World March 4, 2013 Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Chemistry World September 8, 2010 Andrew Turley |
Vince Cable: science cuts are coming Taxpayers should only back research that makes money or is academically exceptional, UK business secretary Vince Cable said today in his first speech on science. |
Chemistry World April 22, 2009 Matt Wilkinson |
Darling budgets for high tech growth Alistair Darling, the UK's Chancellor of the Exchequer, gave a speech which focused heavily on how he wants to produce a 'hi tech Britain that will lead our economic recovery' |
Chemistry World February 2007 Mark Peplow |
Science Stars Rise in the East Collaborate or die. That's the message of a series of reports from the independent thinktank Demos, claiming that British science is in danger of being sidelined unless it tries harder to work with booming Asian nations such as China, India and South Korea. |
Chemistry World November 28, 2008 Matt Wilkinson |
EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market. |
Chemistry World June 5, 2009 Anna Lewcock |
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. |
Chemistry World December 13, 2013 Maria Burke |
UK overtakes US on research quality metric The UK has overtaken the US and now ranks first in one indicator of research quality, according to a new report commissioned by the UK's Department of Business, Innovation and Skills. |
Chemistry World January 18, 2012 Patrick Walter |
Shell shutters UK R&D site The research currently carried out at the facility will be transferred to overseas sites. The announcement has fueled concerns in the UK research community that the country's opportunity to become a high-tech economy is slipping away. |
Chemistry World November 25, 2010 Mike Brown |
Capping scientific migrants A new UK immigration cap could bias against researchers looking to come to the UK. |
Chemistry World September 18, 2012 Laura Howes |
Battery boost for electric cars The UK government, in collaboration with industry, is to create a new UK energy storage R&D center to accelerate the development of batteries for vehicles. |
Chemistry World March 2011 Bea Perks |
Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger. |
Chemistry World September 10, 2015 Matthew Gunther |
Research bodies urge UK government to protect science funding Nearly 200 research organizations have signed an open letter urging the UK government to protect science funding in the 2015 UK spending review. |
Chemistry World June 24, 2011 Andrew Turley |
Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK. |
Pharmaceutical Executive May 1, 2005 Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues. |
Chemistry World February 10, 2015 Emma Stoye |
Science societies urge next UK government to invest more in research The next UK government should invest twice as much in research, according to a joint statement released by the National Academies. |
Chemistry World November 30, 2011 Patrick Walter |
Autumn windfall for UK science and industry The UK government has announced a raft of measures in its autumn statement to try to boost the flagging economy. There is some good news for the research community, as well as the chemical and life science industries. |
Chemistry World February 2, 2011 Andy Extance |
Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations. |
IndustryWeek June 23, 2010 |
By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States. |
Chemistry World December 15, 2009 Sarah Houlton |
Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu. |
Chemistry World July 9, 2013 Daniel Johnson |
Evotec moves business back to UK German drug discovery company Evotec will close its operations in Thane, India, and move them back to its Abingdon, UK, facility. |
Chemistry World March 8, 2011 Andy Extance |
GSK will pay off UK graduate tuition fees Potential undergraduate chemistry students concerned about their prospects in the face of plant closures and increased tuition fees have been given some cheer by pharmaceutical giant GlaxoSmithKline. |
Chemistry World February 4, 2010 Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |